*ST長動(000835.SZ):擬向實控人振興生物藥業借款不超1億元
格隆匯6月21日丨*ST長動(000835.SZ)公佈,公司於2021年6月21日召開第九屆董事會2021年第八次臨時會議,審議通過了《關於擬向山西振興生物藥業有限公司借款暨關聯交易的議案》。
根據公司目前的融資狀況及近期的資金需求,為保證公司經營及重整工作正常開展,公司擬向實際控制人振興生物藥業有限公司借款不超過人民幣1億元。借款額度有效期為12個月,額度在有效期內可分多筆循環滾動使用,借款利率參照銀行等金融機構同期貸款利率水平及實際控制人實際融資成本,但任何一筆借款的利率不得高於中國人民銀行公佈的金融機構同期人民幣貸款基準利率的50%,由雙方在簽訂借款協議時協商確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.